Alnylam Pharmaceuticals (ALNY) Cash & Current Investments (2009 - 2026)

Alnylam Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• Quarterly Cash & Current Investments rose 14.64% year-over-year to $3.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 14.64% YoY) and the FY2025 annual result came in at $2.9 billion, up 197.75% from the prior year.
• Cash & Current Investments was $3.0 billion for Q1 2026 at Alnylam Pharmaceuticals, up from $2.9 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $3.0 billion in Q1 2026 and bottomed at $606.5 million in Q2 2022.
• A 5-year average of $1.6 billion and a median of $1.1 billion in 2025 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 405.73% — and 2023, when it sank 68.38%.
• Alnylam Pharmaceuticals' Cash & Current Investments stood at $2.2 billion in 2022, then advanced by 12.08% to $2.4 billion in 2023, then plunged by 59.77% to $976.8 million in 2024, then jumped by 197.75% to $2.9 billion in 2025, then grew by 3.46% to $3.0 billion in 2026.
• Business Quant data shows ALNY's Cash & Current Investments at $3.0 billion in Q1 2026, $2.9 billion in Q4 2025, and $1.5 billion in Q3 2025.